CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
octaplasbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02050841
NCT02050841Phase 4Completed

An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.

Octapharma·interventional·Posted Jan 31, 2014·Updated Jun 23, 2020

In Brief

A Phase 4 clinical trial evaluating octaplas for Liver Surgery and 3 related conditions. Completed, enrolled 50 participants across 4 sites.

Detailed Summary

The purpose of this study is to investigate the safety, tolerability and efficacy of octaplas in pediatric patients who require replacement of multiple coagulation factors. Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies due to liver disease and/or in pediatric patients requiring cardiac surgery or liver surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 31, 2014
Enrollment StartDec 1, 2014
Primary CompletionDec 4, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.4 years ago

Interventions

octaplasbiological

Octaplas S/D Plasma